The first 3 authors contributed equally to this article.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer
Interim analysis of a prospective randomized noninferiority trial
Article first published online: 19 MAY 2011
DOI: 10.1002/cncr.26119
Copyright © 2011 American Cancer Society
Additional Information
How to Cite
Hu, X., Bao, Y., Zhang, L., Guo, Y., Chen, Y. Y., Li, K. X., Wang, W. H., Liu, Y., He, H. and Chen, M. (2012), Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer. Cancer, 118: 278–287. doi: 10.1002/cncr.26119
- †
The first 3 authors contributed equally to this article.
Publication History
- Issue published online: 16 DEC 2011
- Article first published online: 19 MAY 2011
- Manuscript Revised: 15 FEB 2011
- Manuscript Accepted: 15 FEB 2011
- Manuscript Received: 5 NOV 2010
- Abstract
- Article
- References
- Cited By
Keywords:
- lung cancer;
- small cell;
- limited-stage;
- combined modality treatment;
- radiation target volume
Abstract
BACKGROUND:
Controversies exist with regard to thoracic radiotherapy volumes for limited-stage small cell lung cancer (SCLC). This study compared locoregional progression and overall survival between limited-stage SCLC patients who received thoracic radiotherapy to different target volumes after induction chemotherapy.
METHODS:
Chemotherapy consisted of 6 cycles of etoposide and cisplatin. After 2 cycles of etoposide and cisplatin, patients were randomly assigned to receive thoracic radiotherapy to either the postchemotherapy or prechemotherapy tumor extent as study arm or control. Elective nodal irradiation was omitted for both arms. Forty-five Gy/30Fx/19 days thoracic radiotherapy was administered concurrently with cycle 3 chemotherapy. Prophylactic cranial irradiation was administered to patients who achieved complete remission. An interim analysis was planned when the first 80 patients had been followed for at least 6 months, for consideration of potential inferiority in the study arm.
RESULTS:
Forty-two and 43 patients were randomly assigned to a study arm and a control, respectively. The local recurrence rates were 31.6% (12 of 38) and 28.6% (12 of 42), respectively (P = .81). The isolated nodal failure rates were 2.6% (1 of 38) and 2.4% (1 of 42), respectively (P = 1.00). All isolated nodal failure sites were in the ipsilateral supraclavicular fossa. Mediastinal N3 was the only factor to predict isolated nodal failure (P = .004; odds ratio [OR], 29.33; 95% CI, 2.94-292.38). One-year and 3-year overall survival rates were 80.6%, 36.2%, and 78.9%, 36.4%, respectively (P = .54).
CONCLUSIONS:
Preliminary results indicated that irradiated postchemotherapy tumor extent and omitted elective nodal irradiation did not decrease locoregional control in the study arm, and the overall survival difference was not statistically significant between the 2 arms. Further investigation is warranted. Cancer 2012;. © 2011 American Cancer Society.